May 24, 2004 (Press Release) --
Genetronics and Merck Sign Licensing Agreement for MedPulser(R) DNA Delivery System to Support DNA Vaccine Delivery
Genetronics Biomedical Corporation (Amex: GEB) has signed a collaboration and licensing agreement with Merck & Co., Inc. (NYSE: MRK) to develop and commercialize Genetronics' MedPulser® DNA Delivery System, which will be developed for use with certain of Merck's DNA vaccine programs. This development and commercialization agreement is an extension of an initial evaluation agreement that was established in 2003.
Full details at http://www.investorideas.com/Research/Industries/BioArticles/Genetronics.asp
Genetronics Biomedical Corporation (Amex: GEB) has signed a collaboration and licensing agreement with Merck & Co., Inc. (NYSE: MRK) to develop and commercialize Genetronics' MedPulser® DNA Delivery System, which will be developed for use with certain of Merck's DNA vaccine programs. This development and commercialization agreement is an extension of an initial evaluation agreement that was established in 2003.
Full details at http://www.investorideas.com/Research/Industries/BioArticles/Genetronics.asp

Genetronics and Merck Sign Licensing Agreement for MedPulser(R) DNA Delivery System to Support DNA Vaccine Delivery
Email
Print
SPAM




